We believe great partnerships create great possibilities and are inspired by our partners
As a global biopharmaceutical company, we leverage our agility, R&D capabilities, and global footprint to develop valuable business partnerships that fuel tomorrow’s breakthrough discoveries across our three therapeutic areas: Oncology, Rare Disease and Neuroscience. External innovation is at the heart of our strategy. We believe in the expertise of our partners and value the opportunity to collaborate, bringing our skills, experience, and global reach to accelerate innovation to bring new medicines to patients.
Since 2020, Ipsen has brought in more than 30 best- or first-in-class programs across our pipeline at every stage of development. We are proud that our team comprises talents attracted from pharma, biotech and academia, to drive shared success through creative collaborations.
Oncology
We pioneer treatments in cancer, advancing bold science
Where we plan to expand
- Focus: solid tumours, haematology and precision medicine
- Assets of interest: Best- or first-in-class assets with strong science and meaningful differentiation Biomarker segments
- Market focus: Smaller patient segments attractive for mid-sized companies
Rare Disease
We are breaking new ground in rare bone and liver diseases
Where we plan to expand
- Focus: High unmet needs in under served rare diseases
- Assets of interest: Drive liver & bone franchises; expand to new disease areas
- Market focus: Pursuing assets with a good fitfor clinical development and go-to-market model
Neuroscience
We are pushing the boundaries of science to deliver innovation
Where we plan to expand
- Focus: Rare neurological disorders in pre-proof-of-concept programs; exploring rare and non-rare disorders in Phase III and beyond
- Assets of interest: Expand in non-rare to adjacent areas
- Market focus: Strong innovation and scientific advances
Contact the partnering team
At Ipsen, partnering is personal and purpose-led. Our team is committed to success and has the expertise to deliver it. Contact us to see how together, we can accelerate innovation for patients.
Pipeline
Our robust development pipeline, backed by our expertise and external innovation strategy, supports patients’ health outcomes across Oncology, Rare Disease, and Neuroscience.
Learn morePartnering announcements
02 March 2023
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
09 January 2023
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver…
12 August 2022
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
27 June 2022
Ipsen to acquire Epizyme, expanding its portfolio in oncology
ISS and Externally Sponsored Collaboration
We are ready to consider supporting Investigator Sponsored Studies (ISS) and Externally Sponsored Collaboration because we recognize that this research can play a key role in answering important medical and scientific questions regarding our products and/or their related therapeutic areas. Any support request must be submitted via our dedicated portal.
